Logo image of BCT.CA

BRIACELL THERAPEUTICS CORP (BCT.CA) Stock Fundamental Analysis

Canada - Toronto Stock Exchange - TSX:BCT - CA1079303071 - Common Stock

14.23 CAD
-0.24 (-1.66%)
Last: 11/28/2025, 7:00:00 PM
Fundamental Rating

3

Taking everything into account, BCT scores 3 out of 10 in our fundamental rating. BCT was compared to 23 industry peers in the Biotechnology industry. While BCT has a great health rating, there are worries on its profitability. BCT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BCT has reported negative net income.
In the past year BCT has reported a negative cash flow from operations.
In the past 5 years BCT always reported negative net income.
BCT had a negative operating cash flow in each of the past 5 years.
BCT.CA Yearly Net Income VS EBIT VS OCF VS FCFBCT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

BCT's Return On Assets of -119.59% is in line compared to the rest of the industry. BCT outperforms 43.48% of its industry peers.
With a decent Return On Equity value of -146.16%, BCT is doing good in the industry, outperforming 65.22% of the companies in the same industry.
Industry RankSector Rank
ROA -119.59%
ROE -146.16%
ROIC N/A
ROA(3y)-91.98%
ROA(5y)-72.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCT.CA Yearly ROA, ROE, ROICBCT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K -1K 1.5K

1.3 Margins

BCT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCT.CA Yearly Profit, Operating, Gross MarginsBCT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for BCT has been increased compared to 1 year ago.
Compared to 5 years ago, BCT has more shares outstanding
There is no outstanding debt for BCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCT.CA Yearly Shares OutstandingBCT.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M
BCT.CA Yearly Total Debt VS Total AssetsBCT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -5.51, we must say that BCT is in the distress zone and has some risk of bankruptcy.
BCT has a Altman-Z score (-5.51) which is comparable to the rest of the industry.
BCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.51
ROIC/WACCN/A
WACCN/A
BCT.CA Yearly LT Debt VS Equity VS FCFBCT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 5.03 indicates that BCT has no problem at all paying its short term obligations.
The Current ratio of BCT (5.03) is better than 82.61% of its industry peers.
A Quick Ratio of 5.03 indicates that BCT has no problem at all paying its short term obligations.
The Quick ratio of BCT (5.03) is better than 86.96% of its industry peers.
Industry RankSector Rank
Current Ratio 5.03
Quick Ratio 5.03
BCT.CA Yearly Current Assets VS Current LiabilitesBCT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

BCT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14343.33%.
EPS 1Y (TTM)-14343.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-428.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.83% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y90.98%
EPS Next 2Y40.47%
EPS Next 3Y25.73%
EPS Next 5Y18.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCT.CA Yearly Revenue VS EstimatesBCT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2M 4M 6M 8M 10M
BCT.CA Yearly EPS VS EstimatesBCT.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 0 -50 -100 -150 -200

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCT. In the last year negative earnings were reported.
Also next year BCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCT.CA Price Earnings VS Forward Price EarningsBCT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCT.CA Per share dataBCT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150

4.3 Compensation for Growth

A more expensive valuation may be justified as BCT's earnings are expected to grow with 25.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.47%
EPS Next 3Y25.73%

More info and screens

0

5. Dividend

5.1 Amount

BCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIACELL THERAPEUTICS CORP

TSX:BCT (11/28/2025, 7:00:00 PM)

14.23

-0.24 (-1.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-15 2025-10-15/amc
Earnings (Next)12-15 2025-12-15
Inst Owners9.66%
Inst Owner ChangeN/A
Ins Owners3.94%
Ins Owner ChangeN/A
Market Cap26.75M
Revenue(TTM)N/A
Net Income(TTM)-26.31M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-172.97%
Min EPS beat(2)-353.68%
Max EPS beat(2)7.74%
EPS beat(4)1
Avg EPS beat(4)-134.28%
Min EPS beat(4)-353.68%
Max EPS beat(4)7.74%
EPS beat(8)4
Avg EPS beat(8)-34.83%
EPS beat(12)7
Avg EPS beat(12)-19.86%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-546.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-179.66
EYN/A
EPS(NY)-16.21
Fwd EYN/A
FCF(TTM)-21
FCFYN/A
OCF(TTM)-21
OCFYN/A
SpS0
BVpS13.59
TBVpS13.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -119.59%
ROE -146.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-91.98%
ROA(5y)-72.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.03
Quick Ratio 5.03
Altman-Z -5.51
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14343.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-428.48%
EPS Next Y90.98%
EPS Next 2Y40.47%
EPS Next 3Y25.73%
EPS Next 5Y18.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-14.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.76%
OCF growth 3YN/A
OCF growth 5YN/A

BRIACELL THERAPEUTICS CORP / BCT.CA FAQ

What is the fundamental rating for BCT stock?

ChartMill assigns a fundamental rating of 3 / 10 to BCT.CA.


What is the valuation status for BCT stock?

ChartMill assigns a valuation rating of 1 / 10 to BRIACELL THERAPEUTICS CORP (BCT.CA). This can be considered as Overvalued.


What is the profitability of BCT stock?

BRIACELL THERAPEUTICS CORP (BCT.CA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for BRIACELL THERAPEUTICS CORP?

The Earnings per Share (EPS) of BRIACELL THERAPEUTICS CORP (BCT.CA) is expected to grow by 90.98% in the next year.